Karyopharm Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $30,542 | $38,783 | $42,786 | $33,125 |
Gross Profit | 29,211 | 37,483 | 41,230 | 31,129 |
EBITDA | -19,604 | -20,576 | 32,899 | -31,322 |
EBIT | -19,685 | -20,659 | 32,808 | -31,407 |
Net Income | -30,780 | -32,072 | 23,792 | -37,362 |
Net Change In Cash | 30,542 | 38,783 | 42,786 | 33,125 |
Free Cash Flow | -25,757 | -19,453 | -38,498 | -43,920 |
Cash | 62,476 | 72,828 | 84,806 | 31,087 |
Basic Shares | 125,909 | 125,010 | 154,425 | 115,454 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $145,237 | $146,033 | $157,074 | $209,819 |
Gross Profit | 139,230 | 141,091 | 151,861 | 206,417 |
EBITDA | -38,603 | -118,423 | -139,305 | -96,985 |
EBIT | -38,943 | -118,953 | -139,926 | -97,774 |
Net Income | -76,422 | -143,099 | -165,291 | -124,088 |
Net Change In Cash | 145,237 | 146,033 | 157,074 | 209,819 |
Cost of Revenue | -60,072 | 108,372 | ||
Free Cash Flow | -127,628 | -92,723 | -149,672 | -112,828 |
Cash | 62,476 | 52,231 | 135,188 | 190,459 |
Basic Shares | 126,809 | 114,221 | 81,871 | 75,218 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.24 |
2024-09-30 | -$0.25 |
2024-06-30 | $0.15 |
2024-03-31 | -$0.32 |
